首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1566177

免疫學市場規模、佔有率、成長分析、按藥物類別、按疾病適應症、按分銷管道、按地區 - 行業預測，2024-2031 年

Immunology Market Size, Share, Growth Analysis, By Drug Class, By Disease Indication, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: 2024年10月01日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球免疫學市場規模為958億美元，從2023年的1,074.9億美元成長到2031年的2,699.6億美元，預測期間(2024-2031年)複合年成長率預計將維持在12.20%。

全球免疫學市場是一個快速變化的醫療保健和製藥領域，專注於開拓各種免疫相關疾病的創新治療方法和診斷方法，包括自體免疫疾病、癌症、過敏和感染疾病，這就是我工作的領域。由於這些疾病盛行率不斷上升，對有效免疫療法的需求正在迅速增加。生物技術和分子生物學的最新進展正在促進標靶免疫療法的創建並推動市場成長。然而，也存在阻礙治療方法廣泛使用的重大挑戰，包括飆升的治療費用、嚴格的法規環境和複雜的保險報銷框架。此外，新興國家對尖端治療的認知和獲取有限可能會限制市場擴張。主要障礙包括更好地了解疾病機制、識別生物標記以進行更精確的患者分層以及開發個人化免疫療法，所有這些都與免疫系統的複雜性有關，它與其他身體過程的相互作用錯綜複雜地交織在一起。然而，基因組和蛋白質組技術的進步以及對免疫調節的掌握程度的提高為未來提供了充滿希望的機會。精準醫學的興起以及將免疫策略與其他治療方法結合的可能性正在增加專業治療的前景。總體而言，全球免疫學市場面臨各種挑戰，但應對這些挑戰並利用創新機會可以帶來免疫相關疾病治療的變革性進展。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

AbbVie, Inc.（US）
Janssen Global Services, LLC（US）
Eli Lilly and Company（US）
Novartis AG（Switzerland）
Pfizer Inc.（US）
Bristol-Myers Squibb Company（US）
Merck Sharp & Dohme Corp.（US）
F. Hoffmann-La Roche Ltd.（Switzerland）
Amgen Inc.（US）
Astellas Pharma Inc.（Japan）
UCB SA（Belgium）
Sanofi（France）
Gilead Sciences, Inc.（US）
Regeneron Pharmaceuticals, Inc.（US）
Teva Pharmaceutical Industries Ltd.（Israel）
Takeda Pharmaceutical Company Limited（Japan）
Horizon Therapeutics plc（Ireland）
Aimmune Therapeutics, Inc.（US）
Celgene Corporation（US）
Incyte Corporation（US）
Boehringer Ingelheim GmbH（Germany）
Abbott Laboratories（US）

簡介目錄

Product Code: SQMIG35H2245

Global Immunology Market size was valued at USD 95.8 billion in 2022 and is poised to grow from USD 107.49 billion in 2023 to USD 269.96 billion by 2031, growing at a CAGR of 12.20% during the forecast period (2024-2031).

The global immunology market is a rapidly changing segment within the healthcare and pharmaceutical sectors, focused on developing innovative therapies and diagnostics for various immune-related disorders, such as autoimmune diseases, cancer, allergies, and infectious diseases. Driven by the rising prevalence of these conditions, there is an urgent demand for effective immunological treatments. Recent advancements in biotechnology and molecular biology have facilitated the creation of targeted immunotherapies, propelling market growth. However, the sector also faces significant challenges, including high treatment costs, stringent regulatory environments, and complex reimbursement frameworks that impede the widespread adoption of therapies. Furthermore, limited awareness and access to cutting-edge treatments in developing regions can restrict market expansion. Key hurdles include the need for deeper understanding of disease mechanisms, the identification of biomarkers for more accurate patient stratification, and the development of personalized immunotherapies, all compounded by the intricate nature of the immune system and its interactions with other bodily processes. Nevertheless, promising opportunities lie ahead, driven by advancements in genomic and proteomic technologies and a growing mastery of immune regulation. The rise of precision medicine and the potential integration of immunological strategies with other treatment modalities enhance prospects for specialized interventions. Overall, while the global immunology market confronts various challenges, addressing these issues and leveraging opportunities for innovation can lead to transformative advancements in the treatment of immune-related disorders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immunology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immunology Market Segmental Analysis

Global Immunology Market is segmented by Drug Class, Disease Indication, Distribution Channel, and region. Based on Drug Class, the market is segmented into Monoclonal Antibody, Immunosuppressants, Fusion Proteins, Others. Based on Disease Indication, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Immunology Market

The rapid advancements in biotechnology serve as a crucial market driver for the Global Immunology market, revolutionizing treatment options for immune-related disorders. With the introduction of novel biologics and targeted therapies, such as the FDA-approved bimekizumab for psoriasis and psoriatic arthritis, the therapeutic landscape is witnessing transformative shifts. These innovations not only offer superior efficacy compared to traditional treatments but also enhance patient outcomes significantly. As the demand for effective and tailored therapies rises, the integration of cutting-edge biotechnological developments will continue to propel growth in the immunology sector, fostering further research and investment in this dynamic field.

Restraints in the Global Immunology Market

The global immunology market faces considerable restraints due to the high costs associated with immunological therapies. The intricate processes involved in the development and manufacturing of biologics and targeted therapies contribute to elevated production costs, which are subsequently passed on to patients and healthcare systems. This financial burden restricts access to these innovative treatment options, particularly in developing regions where healthcare budgets are limited. Moreover, the persistent challenge of affordability stifles broader adoption of immunological interventions, hindering advancements in patient care and impeding market growth. As a result, addressing these economic barriers is crucial for the future expansion of the immunology sector.

Market Trends of the Global Immunology Market

The global immunology market is experiencing a significant shift towards personalized medicine, driven by advancements in biomarker development. Companies and researchers are increasingly investing in identifying specific biomarkers that can stratify patient populations, allowing for tailored immunotherapy approaches. This trend not only enhances treatment efficacy but also minimizes adverse reactions by ensuring that patients receive therapies tailored to their unique biological profiles. The growing demand for precision medicine, combined with technological innovations and regulatory support, positions personalized immunology therapies as a pivotal area of growth in the market, promising enhanced patient outcomes and a more targeted approach to immunological diseases.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Immunology Market by Drug Class

Market Overview
Monoclonal Antibody
Immunosuppressants
Fusion Proteins
Others

Immunology Market by Disease Indication

Market Overview
Rheumatoid Arthritis
Psoriatic Arthritis
Plaque Psoriasis
Ankylosing Spondylitis
Inflammatory Bowel Disease
Prophylaxis of Organ Rejection
Others

Immunology Market by Distribution Channel

Market Overview
Offline Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Online Channel

Immunology Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

AbbVie, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Global Services, LLC (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck Sharp & Dohme Corp. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB SA (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Horizon Therapeutics plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aimmune Therapeutics, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments